Down syndrome screening in the first and/or second trimester: Model predicted performance using meta-analysis parameters

被引：81

作者：

Cuckle, H

Benn, P

Wright, D

机构：

[1] Univ Leeds, Leeds LS2 9JT, W Yorkshire, England

[2] Univ Connecticut, Farmington, CT USA

[3] Univ Plymouth, Plymouth PL4 8AA, Devon, England

来源：

SEMINARS IN PERINATOLOGY | 2005年 / 29卷 / 04期

关键词：

Down syndrome; antenatal screening; policy; modeling; sequential;

D O I：

10.1053/j.semperi.2005.05.004

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

引用

页码：252 / 257

页数：6

共 31 条

[21]

2-U

[22] Sequential pathways of testing after first-trimester screening for trisomy 21 [J].

Platt, LD ;

Greene, N ;

Johnson, A ;

Zachary, J ;

Thom, E ;

Krantz, D ;

Simpson, JL ;

Silver, RK ;

Snijders, RJM ;

Goetzl, L ;

Pergament, E ;

Filkins, K ;

Mahoney, MJ ;

Hogge, WA ;

Wilson, RD ;

Mohide, P ;

Hershey, D ;

MacGregor, S ;

Bahado-Singh, R ;

Jackson, LG ;

Wapner, R .

OBSTETRICS AND GYNECOLOGY, 2004, 104 (04) :661-666

[23] MODEL-BASED SCREENING BY RISK WITH APPLICATION TO DOWNS-SYNDROME [J].

ROYSTON, P ;

THOMPSON, SG .

STATISTICS IN MEDICINE, 1992, 11 (02) :257-268

[24] Down's syndrome screening with nuchal translucency at 12+0-14+0 weeks and maternal serum markers at 14+1-17+0 weeks:: a prospective study [J].

Rozenberg, P ;

Malagrida, L ;

Cuckle, H ;

Durand-Zaleski, I ;

Nisand, I ;

Audibert, F ;

Benattar, C ;

Tribalat, S ;

Cartron, M ;

Lemarie, P ;

Stoessel, J ;

Capolagui, P ;

Jansé-Marec, J ;

Barbier, D ;

Allouch, C ;

Perdu, M ;

Roberto, A ;

Lahna, Z ;

Giudicelli, Y ;

Ville, Y .

HUMAN REPRODUCTION, 2002, 17 (04) :1093-1098

[25] Delta-NT or NT MoM: which is the most appropriate method for calculating accurate patient-specific risks for trisomy 21 in the first trimester? [J].

Spencer, K ;

Bindra, R ;

Nix, ABJ ;

Heath, V ;

Nicolaides, KH .

ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2003, 22 (02) :142-148

[26] The effect of temporal variation in biochemical markers of trisomy 21 across the first and second trimesters of pregnancy on the estimation of individual patient-specific risks and detection rates for Down's syndrome [J].

Spencer, K ;

Crossley, JA ;

Aitken, DA ;

Nix, ABJ ;

Dunstan, FDJ ;

Williams, K .

ANNALS OF CLINICAL BIOCHEMISTRY, 2003, 40 :219-231

[27] Temporal changes in maternal serum biochemical markers of trisomy 21 across the first and second trimester of pregnancy [J].

Spencer, K ;

Crossley, JA ;

Aitken, DA ;

Nix, ABJ ;

Dunstan, FDJ ;

Williams, K .

ANNALS OF CLINICAL BIOCHEMISTRY, 2002, 39 :567-576

[28] Nuchal translucency and gestational age [J].

Wald, N ;

Rodeck, C ;

Rudnicka, A ;

Hackshaw, A .

PRENATAL DIAGNOSIS, 2004, 24 (02) :150-151

[29] First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS) [J].

Wald, NJ ;

Rodeck, C ;

Hackshaw, AK ;

Walters, J ;

Chitty, L ;

Mackinson, AM .

JOURNAL OF MEDICAL SCREENING, 2003, 10 (02) :56-104

[30] Contingent screening for Down syndrome is an efficient alternative to non-disclosure sequential screening [J].

Wright, D ;

Bradbury, I ;

Benn, P ;

Cuckle, H ;

Ritchie, K .

PRENATAL DIAGNOSIS, 2004, 24 (10) :762-766

← 1 2 3 4 →